Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg



Status:Completed
Conditions:Prostate Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/28/2019
Start Date:February 2016
End Date:December 19, 2017

Use our guide to learn which trials are right for you!

An Open-Label, Single-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma - SAFETY EXTENSION

This is a safety extension of up to 12 months of additional treatment with LMIS 50 mg after
the subject has completed 12 months of treatment under Protocol FP01C-13-001 and remain
eligible for continued treatment with androgen deprivation therapy. Subjects participating in
Protocol FP01C-13-001-EX will be followed for safety only.

This is a multi-center, open-label, single-arm safety extension study. After completing 12
months of treatment with LMIS 50 mg under Protocol FP01C-13-001 (with last dose under
Protocol FP01C-13-001 approximately 6 months prior to Day 0 or Protocol FP01C-13-001-EX) and
providing a written informed consent, subjects will be screened against baseline
inclusion/exclusion criteria necessary for study eligibility. Eligible subjects will receive
LMIS 50 mg from the prefilled syringes (without dilution or other mixing) in up to two single
subcutaneous injections given 6 months apart.

Inclusion Criteria:

1. Complete 12 months of treatment with LMIS 50 mg under Protocol FP01C-13-001. If a
subject wishes to enter the Extension study after more than 28 days following his end
of study visit for Protocol FP01C-13-001, his serum testosterone level should be
repeated at the screening visit to confirm that his castrate-level testosterone has
been maintained.

2. Laboratory values

- Absolute neutrophil count ≥ 1,500 cells/µL

- Platelets≥100,000 cells/µL

- Hemoglobin ≥ 10 gm/dL

- Total bilirubin ≤ 1.5 × upper limit of normal (ULN)

- Aspartate Transaminase (AST/SGOT) ≤ 2.5 × ULN

- Alanine Aminotransferase (ALT/SGPT) ≤ 2.5 × ULN

- Serum creatinine ≤ 1.5 mg/dL

- Lipid profile within acceptable range according to investigator's opinion

- Serum glucose within acceptable range according to investigator's opinion

- HgbA1c within acceptable range according to investigator's opinion

- Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to
investigator's judgment

- Urinalysis within normal range according to the investigator's judgment

3. Agree to use male contraceptive methods during study trial

4. In the Investigator's opinion, the ability to understand the nature of the study and
any hazards of participation, and to communicate satisfactorily with the Investigator
and to participate in, and to comply with, the requirements of the entire protocol

5. All aspects of the protocol explained and written informed consent obtained *If the
patient completed 12 months of treatment with LMIS 50 mg more than 28 days prior to
entering the Extension study, the Eastern Cooperative Oncology Group (ECOG), Physical
Examination (PE), ECG, laboratory and Prostate Specific Antigen (PSA) tests should be
repeated.

If the patient has completed 12 months of treatment with LMIS 50 mg under Protocol
FP01C-13-001 within the last 28 days, they will be allowed to enter the Extension study
without repeating the testosterone measurements, ECG, PE, laboratory and the PSA tests

Exclusion Criteria:

1. Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti-androgen
therapy other than LMIS 50 mg under Protocol FP01C-13-001 for treatment of carcinoma
of the prostate during the subject's participation in Protocol FP01C-13-001. Radiation
for pain control will be allowed during the study.

2. Receipt of any Luteinizing Hormone-releasing Hormone (LHRH) suppressive therapy within
6 months of Screening Visit other than LMIS 50 mg under Protocol FP01C-13-001

3. Subject has used prohibited treatments as listed in the Section 8.2 during
participation in Protocol FP01C-13-001.

4. Any pathological event, clinical adverse event, or any change in the subject's status
at the end of FP01C-13-001 giving indication to the investigator that further
participation in the study may not be the best interest of the subject

5. Investigator considers that it is no longer feasible for the subject to be included in
a study of LMIS 50 mg

6. Subjects with persistent, non-castrate testosterone levels judged by the investigator

7. Uncontrolled intercurrent illness that would jeopardize the subject's safety,
interfere with the objectives of the protocol, or limit the subject's compliance with
study requirements, as determined by the Investigator in consultation with the Sponsor
We found this trial at
7
sites
Lawrenceville, New Jersey 08648
Principal Investigator: Russell Freid, MD
Phone: 609-895-0735
?
mi
from
Lawrenceville, NJ
Click here to add this to my saved trials
Burien, Washington 98166
Principal Investigator: Jeffery Frankel, MD
Phone: 206-243-3701
?
mi
from
Burien, WA
Click here to add this to my saved trials
Concord, North Carolina 28025
Principal Investigator: David Lipsitz, MD
Phone: 704-786-2931
?
mi
from
Concord, NC
Click here to add this to my saved trials
Homewood, Alabama 35209
Principal Investigator: George Adams, MD
Phone: 205-414-4423
?
mi
from
Homewood, AL
Click here to add this to my saved trials
Meridian, Idaho 83642
Principal Investigator: Joseph William, MD
Phone: 208-639-4938
?
mi
from
Meridian, ID
Click here to add this to my saved trials
823 82nd Parkway, Suite B
Myrtle Beach, South Carolina 29572
(843) 449-1010 ext.268
Principal Investigator: Neal Shore, MD
Phone: 843-449-1010
Carolina Urologic Research Center Carolina Urologic Research Center (CURC) has been recognized both nationally and...
?
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
San Diego, California 92123
?
mi
from
San Diego, CA
Click here to add this to my saved trials